



National Institutes of Health  
Bethesda, Maryland 20205  
National Cancer Institute  
Building 37, Room 6A09  
(301) 496-6007

March 17, 1982

Harold E. Varmus, M.D.  
Department of Microbiology  
and Immunology  
University of California  
School of Medicine  
San Francisco, California 94143

Dear Harold,

I haven't heard further from you on this nomenclature business. What and when do we do anything?

I am also writing to ask if you would like to visit us on your way to or from Cold Spring Harbor in May (if you are going to the meeting). I realize you gave a seminar recently, but we would enjoy very much having you for a more informal smaller seminar and some discussions. Things are moving rapidly with the HTLV story. We have many new isolates in several areas of the world. We have it cloned, the complete amino acid sequence of p24 is finished (Oroszlan), and we have definitive evidence that the virus in Japan is (as obviously anticipated from the seroepidemiology data), HTLV. There are other areas of the world where the disease and virus are endemic. We are beginning to define these now. Like the Japanese we have transmitted it to human mature T-cells.

If you do come I would like to discuss these things further and talk to you about some ideas. Let me know.

Kind regards.

Sincerely yours,

A handwritten signature in cursive script, appearing to read "Bob", is written above the printed name.

Robert C. Gallo

RCG/am